Provexis plc (AIM: PXS)
London
· Delayed Price · Currency is GBP · Price in GBX
0.650
0.00 (0.00%)
Jan 17, 2025, 3:44 PM GMT+1
Provexis Revenue
Provexis had revenue of 785.35K GBP in the half year ending September 30, 2024, with 337.84% growth. This brings the company's revenue in the last twelve months to 1.20M, up 100.60% year-over-year. In the fiscal year ending March 31, 2024, Provexis had annual revenue of 801.96K with 105.68% growth.
Revenue (ttm)
1.20M
Revenue Growth
+100.60%
P/S Ratio
12.15
Revenue / Employee
599.89K
Employees
2
Market Cap
15.25M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 801.96K | 412.05K | 105.68% |
Mar 31, 2023 | 389.92K | -36.25K | -8.51% |
Mar 31, 2022 | 426.17K | -79.16K | -15.67% |
Mar 31, 2021 | 505.33K | 157.39K | 45.24% |
Mar 31, 2020 | 347.94K | 25.75K | 7.99% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |